In brief: ResMed, Meditech, Ventracor
Friday, 04 February, 2005
ResMed (ASX:RMD) shares were up almost 5 per cent today after the company announced record revenue and income results for the quarter ended December 31. Revenue for the quarter was US$103.9 million, a 26 per cent increase over the same quarter last year. Net income for the quarter was US$17.4 million.
Bob Moses has announced that he will not seek re-election as chairman of Meditech (ASX:MTR) at the company's annual general meeting, to be held in March. Meditech intends to appoint a new director by the end of the first quarter.
Ventracor (ASX:VCR) has received permission to begin recruiting patients for the CE Mark trial of its VentrAssist heart pump in Norway through the Rikshopitalet University Hospital in Oslo, one of the largest heart transplant centres in Europe.
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
Newborns have elevated levels of an Alzheimer's biomarker
What do the brains of newborns and patients with Alzheimer's disease have in common? Both...
